Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results.
In this video, Anjay Rastogi, MD, PhD, professor and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, discusses the screening process for chronic kidney disease.
Compared with eGFRcr, a 30% lower eGFRcys was associated with higher rates of all-cause mortality, cardiovascular events, and kidney disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback